You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,707,270


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,707,270 protect, and when does it expire?

Patent 9,707,270 protects PRIALT and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 9,707,270
Title:Method for administering .omega.-conopeptide
Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the .omega.-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
Inventor(s): Ellis; David J. (Los Altos, CA), Miljanich; George P. (Redwood City, CA), Shields; David E. (San Lorenzo, CA)
Assignee: JAZZ PHARMACEUTICALS INTERNATIONAL LIMITED (Hamilton, BM)
Application Number:14/788,524
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patents: A Detailed Analysis

Introduction

Patents are a crucial component of intellectual property protection, allowing inventors and innovators to safeguard their creations and reap the benefits of their hard work. The landscape of patent law, particularly in the United States, is complex and constantly evolving. This article will delve into the key aspects of patent scope and claims, using the context of U.S. Patent 9,707,270 as a reference point, and explore recent updates and best practices in patent law.

What is a Patent?

A patent is a form of intellectual property that gives its owner the legal right to exclude others from making, using, selling, and importing an invention for a certain period of time, usually 20 years from the date of filing. Patents are granted by the U.S. Patent and Trademark Office (USPTO) after a thorough examination process to ensure the invention is novel, nonobvious, and enabled[2].

The Patenting Process

The journey to obtaining a patent involves several steps. It typically begins with the filing of a provisional patent application, which provides a one-year period to decide whether to proceed with a non-provisional patent application. The non-provisional application is then reviewed by a patent examiner, a process known as patent prosecution, which can take several years. If the application is successful, the patent is granted; otherwise, it may be abandoned or appealed[2].

Patent Scope and Claims

Definition of Patent Scope

Patent scope refers to the breadth and depth of protection afforded by a patent. It is determined by the claims of the patent, which are the specific descriptions of the invention that define its boundaries. The scope of a patent is critical because it determines what is protected and what is not[3].

Importance of Claim Language

The language used in patent claims is pivotal. Independent claim length and independent claim count are simple yet effective metrics for measuring patent scope. Research has shown that narrower claims are associated with a higher probability of grant and a shorter examination process compared to broader claims[3].

Recent Updates in AI Patent Eligibility

2024 USPTO Guidance Update

The USPTO's 2024 guidance update on AI patent eligibility is a significant development. This update, prompted by Executive Order 14110, aims to clarify the process for determining the patent eligibility of AI-related inventions. Key takeaways include:

  • Integration into Practical Application: The update emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

  • AI-Assisted Inventions: The guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

  • Incorporation of Recent Case Law: The update integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations relevant for AI inventions. This helps promote consistency and clarity in the application of patent eligibility criteria[1].

Examples and Practical Applications

The USPTO has introduced new examples specifically tailored to AI technologies. For instance, Example 48 illustrates how claims involving specific applications of AI, such as using separated audio components in a speech recognition system, can meet the eligibility criteria by demonstrating a practical application. This example highlights the importance of specifying the use of the invention in a real-world context to ensure patent eligibility[1].

Drafting Effective Patent Claims

Novelty and Nonobviousness

Patent claims must be novel and nonobvious. This means the invention must be new and not obvious to a person with ordinary skill in the relevant field. Claims that are too broad or lack specificity may face rejections during the examination process[2].

Enablement

The patent application must describe the invention in sufficient detail to allow someone with ordinary skill in the art to make and use the invention without undue experimentation. This requirement ensures that the invention is fully disclosed and can be replicated[2].

Real-World Applications

Highlighting the real-world applications of the claimed method or system is crucial. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field can bolster the argument for patent eligibility[1].

International Patent Considerations

Patent Cooperation Treaty (PCT)

For inventions with global commercial potential, a PCT application can be filed to preserve the right to file patents in 153 countries within 30 months of the earliest priority date. However, this process is expensive and typically only pursued if there is a high value and near-term commercial licensing opportunities[2].

Costs and Commercialization

Financial Considerations

The cost of drafting and filing a patent application can be substantial, ranging from $8,000 to $20,000 for a U.S. non-provisional patent application. International patents can cost several times more. These costs are often borne by commercial partners if the invention has significant commercial value[2].

Commercial Partnerships

Commercial partners often play a crucial role in the patenting process, especially in covering the costs associated with patent prosecution. Early identification of a commercial partner can significantly influence the decision to proceed with patenting an invention[2].

Small Claims Patent Court

Need for a Small Claims Court

There has been ongoing discussion about the need for a small claims patent court to address the high costs and complexities associated with patent litigation. The Administrative Conference of the United States (ACUS) has conducted studies and gathered public comments on this issue, highlighting the feasibility and potential structure of such a court[5].

Key Takeaways

  • Patent Scope and Claims: The scope of a patent is defined by its claims, and narrower claims are generally more successful in the examination process.
  • AI Patent Eligibility: The 2024 USPTO guidance update clarifies that AI-assisted inventions are evaluated based on the claimed invention itself, and integrating judicial exceptions into practical applications is crucial.
  • International Considerations: PCT applications can be used to preserve global patent rights, but they are costly and typically reserved for high-value inventions.
  • Financial and Commercial Aspects: Patenting is expensive, and commercial partnerships can be vital in covering these costs.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies[1].

How do you determine the scope of a patent?

The scope of a patent is determined by its claims, with metrics such as independent claim length and independent claim count providing insights into the breadth and depth of protection[3].

What are the key elements of drafting effective patent claims?

Effective patent claims must be novel, nonobvious, and enabled. They should also specify real-world applications to ensure patent eligibility[1][2].

What is the role of commercial partners in the patenting process?

Commercial partners can cover the costs associated with patent prosecution and are often crucial in deciding whether to proceed with patenting an invention, especially if they see significant commercial value[2].

Why is there a discussion about a small claims patent court?

The discussion is driven by the need to address the high costs and complexities of patent litigation, making it more accessible and affordable for smaller entities to protect their intellectual property[5].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Intellectual Property Protection - KU Office of Research
  3. Patent Claims and Patent Scope - SSRN
  4. Records of the Patent and Trademark Office - National Archives
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,707,270

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE ⤷  Subscribe
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No ⤷  Subscribe ⤷  Subscribe TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE ⤷  Subscribe
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE ⤷  Subscribe
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,707,270

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2540895 ⤷  Subscribe
Canada 2930900 ⤷  Subscribe
European Patent Office 1689401 ⤷  Subscribe
Japan 2007507538 ⤷  Subscribe
Japan 2011173931 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2005032556 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.